Concepedia
Statistics
Publications
10
Citations
898
H-Index
Active since
1995
Affiliations
University of Alberta(Current)
Novartis (United States)
BC Cancer Agency
University of British Columbia
Daniel E. Lopes de Menezes is an author at University of Alberta specializing in oncology, pharmacology, and drug delivery.
Publications per year
1995–2007
Pharmacokinetics of long-circulating liposomes
Theresa M. Allen, Christian Hansen, Daniel E. Lopes de Menezes · Advanced Drug Delivery Reviews · 1995 · 305 citations
Pharmacy, Pharmaceutics, Pharmacokinetics +10
CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>
Archie Tse, Katherine G. Rendahl, Tahir Sheikh et al. · Clinical Cancer Research · 2007 · 150 citations
Medicine, Medicinal Chemistry, Pharmacology +17
CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia
Daniel E. Lopes de Menezes, Jing Peng, Evelyn N. Garrett et al. · Clinical Cancer Research · 2005 · 112 citations · Full text
Medicine, Oncology, Pharmacology +16
Long-circulating, polyethylene glycol-grafted immunoliposomes
Samuel Zalipsky, Christian Hansen, Daniel E. Lopes de Menezes et al. · Journal of Controlled Release · 1996 · 74 citations
Pharmacy, Immunology, Molecular Pharmaceutics +11
Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells
Daniel E. Lopes de Menezes, Marc Kirchmeier, Jean-François Gagné et al. · Journal of Liposome Research · 1999 · 71 citations
Pharmacy, Oncology, Pharmacology +14
1–5 of 10